RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

LOS ALTOS, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned interventional oncologist Thierry de Baère, MD, PhD to RenovoRx’s Scientific Advisory Board (SAB).

Read more at globenewswire.com